Home › Neoplasms by Histologic Type › Missouri › St. Louis
Neoplasms by Histologic Type clinical trials in St. Louis, MO
4 studies for Neoplasms by Histologic Type are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- Washington University in St. Louis School of Medicine, St Louis
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
- Siteman Cancer Center at Washington University, St Louis
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Washington University School of Medicine, St Louis
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- Washington University Infusion Center Pharmacy, St Louis
Neoplasms by Histologic Type trials in other cities
- Boston, MA5 studies
- Chicago, IL5 studies
- Houston, TX4 studies
- Atlanta, GA4 studies
- Los Angeles, CA4 studies
- Nashville, TN3 studies
- Cedar Rapids, IA3 studies
- Dallas, TX3 studies
- San Francisco, CA3 studies
- Clifton, NJ3 studies
- New York City, NY3 studies
- Tampa, FL3 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer68 studies
- Breast Cancer63 studies
- Metastatic Cancer52 studies
- Cancer (all types)51 studies
- Colorectal Cancer51 studies
- Prostate Cancer45 studies
- Ovarian Cancer37 studies
- Lung Cancer37 studies
- Pancreatic Cancer33 studies
- Head and Neck Squamous Cell Carcinoma32 studies
- Endometrial Cancer29 studies
- Multiple Myeloma26 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.